Global Liver Diseases Therapeutics Market Report 2024

Liver Diseases Therapeutics Global Market Report 2025 – By Disease Type( Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-Induced, Liver Cancer ), By Treatment( Antiviral, Vaccines, Chemotherapy, Immunosuppressive Agents, Corticosteroids ), By End User( Hospitals, Ambulatory Surgery Centers, Other End Users ) – Market Size, Trends, And Global Forecast 2025-2034

Liver Diseases Therapeutics Global Market Report 2025

Report Price : $4490.00 | Pages : 200 | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Liver Diseases Therapeutics Global Market Report 2025

Proud Members Of

checkslacipN checkaoirsN checkscipN

Liver Diseases Therapeutics Market Definition

Liver disease therapeutics refers to the treatment of numerous types of liver illnesses, diseases brought on by viruses, including hepatitis A, B, and C. Liver disease therapeutics are essential for enhancing the quality of life for those impacted by liver conditions and alleviating the overall strain of liver disease on healthcare systems.

The main disease types of liver disease therapeutics are hepatitis, non-alcoholic fatty liver disease, alcohol-induced, and liver cancer. Hepatitis refers to an inflammation of the liver that is caused by a variety of infectious viruses and noninfectious agents leading to a range of health problems, some of which can be fatal. The treatment is antiviral, vaccines, chemotherapy, immunosuppressive agents, and corticosteroids. The end-users included hospitals, ambulatory surgery centers, and other end-users.

Liver Diseases Therapeutics Market Segmentation

The liver diseases therapeutics market covered in this report is segmented –

1) By Disease Type: Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-Induced, Liver Cancer

2) By Treatment: Antiviral, Vaccines, Chemotherapy, Immunosuppressive Agents, Corticosteroids

3) By End User: Hospitals, Ambulatory Surgery Centers, Other End Users

Subsegments:

1) By Hepatitis: Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D

2) By Non-Alcoholic Fatty Liver Disease (NAFLD): Non-Alcoholic Steatohepatitis (NASH), Simple Fatty Liver

3) By Alcohol-Induced Liver Disease: Alcoholic Hepatitis, Alcoholic Cirrhosis

4) By Liver Cancer: Hepatocellular Carcinoma (HCC), Cholangiocarcinoma

Liver Diseases Therapeutics Market Size and growth rate 2025 to 2029: Graph

Liver Diseases Therapeutics Market Size 2025 And Growth Rate

The liver diseases therapeutics market size has grown strongly in recent years. It will grow from $14.16 billion in 2024 to $15.23 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to high prevalence of liver diseases, alcohol consumption patterns, advancements in diagnostics, obesity and metabolic syndrome, awareness and screening programs, government initiatives for hepatitis control.

Liver Diseases Therapeutics Market Growth Forecast

The liver diseases therapeutics market size is expected to see strong growth in the next few years. It will grow to $20.78 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to precision medicine approaches, innovations in RNA therapeutics, focus on fibrosis treatments, patient advocacy and support groups, development of vaccines for hepatitis, regulatory support for orphan drugs. Major trends in the forecast period include advancements in treatment for hepatitis c, emergence of novel therapies for liver fibrosis, exploration of immunotherapies, telemedicine and remote monitoring, focus on nutritional interventions.

Liver Diseases Therapeutics Market Driver: Elevating Prevalence Of Liver Diseases Fuels Growth In Liver Disease Therapeutics Market

The rising prevalence of liver diseases is expected to propel the growth of the liver disease therapeutics market going forward. Liver disease refers to any condition that has been affecting the liver. Liver disease therapeutics help in treating liver diseases through various treatments. For instance, in April 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, in 2022, the mortality rate from liver disease in individuals under 75 years old in England rose to 21.4 per 100,000 population, with males experiencing 6,664 premature deaths compared to 3,929 for females. Therefore, the rising prevalence of liver diseases drives the growth of the liver disease therapeutics market.

Liver Diseases Therapeutics Market Driver: Expanding Geriatric Population Fuels Low-Density Polyethylene Market Growth

The growing geriatric population is expected to propel the growth of the low-density polyethylene market going forward. The geriatric population refers to the segment of the population composed of older individuals or senior citizens who have reached or surpassed a certain age, typically associated with retirement and the later stages of life. Liver disease therapeutics are used in the geriatric population to address liver-related health issues that improve the quality of life and overall health of elderly individuals with liver-related conditions and to address their liver health effectively. For instance, in January 2024, according to the Population Reference Bureau, a Kenya-based Nonprofit organization, the population of Americans aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, a 47% increase. This age group’s share of the overall population is also projected to rise from 17% to 23% during the same period. Therefore, the growing pharmaceutical industry is driving the growth of the low-density polyethylene market.

Global Liver Diseases Therapeutics Market Major Players

Major companies operating in the liver diseases therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Limited, Valeant Pharmaceuticals, Watson Pharmaceuticals Inc., AstraZeneca PLC, Gilead Sciences Inc., Endo International PLC, Alnylam Pharmaceuticals Inc., Provectus Biopharmaceuticals Inc., Intercept Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., CymaBay Therapeutics Inc., Viking Therapeutics Inc., Madrigal Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Enanta Pharmaceuticals Inc.

Global Liver Diseases Therapeutics Market Trend: Strategic Partnerships Transforming The Landscape Of Liver Disease Therapeutics

Strategic partnerships are a key trend gaining popularity in the liver disease therapeutics market. Major companies operating in the liver diseases therapeutics market are undergoing collaborations to strengthen their position in the liver diseases therapeutics market. For instance, in January 2022, Aligos Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, collaborated with Merck & Co, a US-based company operating in liver disease therapeutics. This collaboration is to discover and develop oligonucleotide therapies for non-alcoholic steatohepatitis.

Global Liver Diseases Therapeutics Market Trend: Revolutionizing Liver Disease Therapeutics With Ai-Powered Technology

Major companies operating in the liver disease therapeutics market are focusing on innovative technologies, such as artificial intelligence, to help clinicians identify patients with liver fibrosis early in their disease progression. Artificial intelligence in liver disease therapeutics refers to the application of advanced computational algorithms and machine learning techniques to analyze medical data, aiding in early detection, diagnosis, and personalized treatment strategies for liver diseases. For instance, in February 2023, Predictive Health Intelligence, a UK-based healthcare information management company, launched the hepatoSIGHT. hepatoSIGHT, an innovative AI-powered tool that can predict liver fibrosis in patients with chronic liver disease. It is a case-finding and cohort mapping tool designed to identify patients at risk of chronic liver disease (CLD). It is a secure, intuitive, and easy-to-use system that can review millions of lines of data within seconds to identify patients who meet specified criteria. Moreover, it has features such as comprehensive data analysis, machine learning algorithms, real-time risk stratification, and an easy-to-use interface.

Liver Diseases Therapeutics Market Merger And Acquisition: Genfit Bolsters Liver Disease Therapeutics Portfolio Through Acquisition Of Versantis

In September 2022, GENFIT, a France-based biopharmaceutical company, acquired Versantis for an undisclosed amount. This acquisition of Versantis’ expertise with GENFIT’s know-how in conducting complex development programs in liver diseases strengthens and accelerates research and development and significantly expands GENFIT’s pipeline. Versantis is a Switzerland-based company operating in liver disease therapeutics.

Regional Outlook For The Global Liver Diseases Therapeutics Market

North America was the largest region in the liver diseases therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the liver diseases therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Liver Diseases Therapeutics Market?

The liver diseases therapeutics market includes revenues earned by entities by diagnosis such as imaging, laboratory tests, endoscopy, and biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Liver Diseases Therapeutics Industry?

The liver diseases therapeutics market research report is one of a series of new reports from The Business Research Company that provides liver diseases therapeutics market statistics, including liver diseases therapeutics industry global market size, regional shares, competitors with a liver diseases therapeutics market share, detailed liver diseases therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the liver diseases therapeutics industry. This liver diseases therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Liver Diseases Therapeutics Market Report Forecast Analysis
Report AttributeDetails
Market Size Value In 2025 $15.23 billion
Revenue Forecast In 2034 $20.78 billion
Growth Rate CAGR of 8.1% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Disease Type: Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-Induced, Liver Cancer
2) By Treatment: Antiviral, Vaccines, Chemotherapy, Immunosuppressive Agents, Corticosteroids
3) By End User: Hospitals, Ambulatory Surgery Centers, Other End Users Subsegments: 1) By Hepatitis: Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D
2) By Non-Alcoholic Fatty Liver Disease (NAFLD): Non-Alcoholic Steatohepatitis (NASH), Simple Fatty Liver
3) By Alcohol-Induced Liver Disease: Alcoholic Hepatitis, Alcoholic Cirrhosis
4) By Liver Cancer: Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Limited, Valeant Pharmaceuticals, Watson Pharmaceuticals Inc., AstraZeneca PLC, Gilead Sciences Inc., Endo International PLC, Alnylam Pharmaceuticals Inc., Provectus Biopharmaceuticals Inc., Intercept Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., CymaBay Therapeutics Inc., Viking Therapeutics Inc., Madrigal Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Enanta Pharmaceuticals Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Liver Diseases Therapeutics Market Characteristics

    3. Liver Diseases Therapeutics Market Trends And Strategies

    4. Liver Diseases Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

    5. Global Liver Diseases Therapeutics Growth Analysis And Strategic Analysis Framework

    5.1. Global Liver Diseases Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

    5.2. Analysis Of End Use Industries

    5.3. Global Liver Diseases Therapeutics Market Growth Rate Analysis

    5.4. Global Liver Diseases Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

    5.5. Global Liver Diseases Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

    5.6. Global Liver Diseases Therapeutics Total Addressable Market (TAM)

    6. Liver Diseases Therapeutics Market Segmentation

    6.1. Global Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hepatitis

    Non-Alcoholic Fatty Liver Disease

    Alcohol-Induced

    Liver Cancer

    6.2. Global Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Antiviral

    Vaccines

    Chemotherapy

    Immunosuppressive Agents

    Corticosteroids

    6.3. Global Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hospitals

    Ambulatory Surgery Centers

    Other End Users

    6.4. Global Liver Diseases Therapeutics Market, Sub-Segmentation Of Hepatitis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hepatitis A

    Hepatitis B

    Hepatitis C

    Hepatitis D

    6.5. Global Liver Diseases Therapeutics Market, Sub-Segmentation Of Non-Alcoholic Fatty Liver Disease (NAFLD), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Non-Alcoholic Steatohepatitis (NASH)

    Simple Fatty Liver

    6.6. Global Liver Diseases Therapeutics Market, Sub-Segmentation Of Alcohol-Induced Liver Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Alcoholic Hepatitis

    Alcoholic Cirrhosis

    6.7. Global Liver Diseases Therapeutics Market, Sub-Segmentation Of Liver Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hepatocellular Carcinoma (HCC)

    Cholangiocarcinoma

    7. Liver Diseases Therapeutics Market Regional And Country Analysis

    7.1. Global Liver Diseases Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    7.2. Global Liver Diseases Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8. Asia-Pacific Liver Diseases Therapeutics Market

    8.1. Asia-Pacific Liver Diseases Therapeutics Market Overview

    Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.3. Asia-Pacific Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.4. Asia-Pacific Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    9. China Liver Diseases Therapeutics Market

    9.1. China Liver Diseases Therapeutics Market Overview

    9.2. China Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.3. China Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.4. China Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    10. India Liver Diseases Therapeutics Market

    10.1. India Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.2. India Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.3. India Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11. Japan Liver Diseases Therapeutics Market

    11.1. Japan Liver Diseases Therapeutics Market Overview

    11.2. Japan Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.3. Japan Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.4. Japan Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12. Australia Liver Diseases Therapeutics Market

    12.1. Australia Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.2. Australia Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.3. Australia Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13. Indonesia Liver Diseases Therapeutics Market

    13.1. Indonesia Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.2. Indonesia Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.3. Indonesia Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14. South Korea Liver Diseases Therapeutics Market

    14.1. South Korea Liver Diseases Therapeutics Market Overview

    14.2. South Korea Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.3. South Korea Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.4. South Korea Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15. Western Europe Liver Diseases Therapeutics Market

    15.1. Western Europe Liver Diseases Therapeutics Market Overview

    15.2. Western Europe Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.3. Western Europe Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.4. Western Europe Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16. UK Liver Diseases Therapeutics Market

    16.1. UK Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.2. UK Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.3. UK Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17. Germany Liver Diseases Therapeutics Market

    17.1. Germany Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.2. Germany Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.3. Germany Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18. France Liver Diseases Therapeutics Market

    18.1. France Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.2. France Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.3. France Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19. Italy Liver Diseases Therapeutics Market

    19.1. Italy Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.2. Italy Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.3. Italy Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20. Spain Liver Diseases Therapeutics Market

    20.1. Spain Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.2. Spain Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.3. Spain Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21. Eastern Europe Liver Diseases Therapeutics Market

    21.1. Eastern Europe Liver Diseases Therapeutics Market Overview

    21.2. Eastern Europe Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.3. Eastern Europe Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.4. Eastern Europe Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22. Russia Liver Diseases Therapeutics Market

    22.1. Russia Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.2. Russia Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.3. Russia Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23. North America Liver Diseases Therapeutics Market

    23.1. North America Liver Diseases Therapeutics Market Overview

    23.2. North America Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.3. North America Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.4. North America Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24. USA Liver Diseases Therapeutics Market

    24.1. USA Liver Diseases Therapeutics Market Overview

    24.2. USA Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.3. USA Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.4. USA Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25. Canada Liver Diseases Therapeutics Market

    25.1. Canada Liver Diseases Therapeutics Market Overview

    25.2. Canada Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.3. Canada Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.4. Canada Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26. South America Liver Diseases Therapeutics Market

    26.1. South America Liver Diseases Therapeutics Market Overview

    26.2. South America Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.3. South America Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.4. South America Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27. Brazil Liver Diseases Therapeutics Market

    27.1. Brazil Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.2. Brazil Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.3. Brazil Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28. Middle East Liver Diseases Therapeutics Market

    28.1. Middle East Liver Diseases Therapeutics Market Overview

    28.2. Middle East Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.3. Middle East Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.4. Middle East Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29. Africa Liver Diseases Therapeutics Market

    29.1. Africa Liver Diseases Therapeutics Market Overview

    29.2. Africa Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.3. Africa Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.4. Africa Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    30. Liver Diseases Therapeutics Market Competitive Landscape And Company Profiles

    30.1. Liver Diseases Therapeutics Market Competitive Landscape

    30.2. Liver Diseases Therapeutics Market Company Profiles

    30.2.1. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.2. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

    30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis

    30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

    31. Liver Diseases Therapeutics Market Other Major And Innovative Companies

    31.1. GlaxoSmithKline PLC

    31.2. Abbott Laboratories Inc.

    31.3. Pfizer Inc.

    31.4. Sanofi SA

    31.5. Johnson & Johnson Services Inc.

    31.6. Bayer AG

    31.7. AbbVie Inc.

    31.8. Takeda Pharmaceutical Company Limited

    31.9. Valeant Pharmaceuticals

    31.10. Watson Pharmaceuticals Inc.

    31.11. AstraZeneca PLC

    31.12. Gilead Sciences Inc.

    31.13. Endo International PLC

    31.14. Alnylam Pharmaceuticals Inc.

    31.15. Provectus Biopharmaceuticals Inc.

    32. Global Liver Diseases Therapeutics Market Competitive Benchmarking And Dashboard

    33. Key Mergers And Acquisitions In The Liver Diseases Therapeutics Market

    34. Recent Developments In The Liver Diseases Therapeutics Market

    35. Liver Diseases Therapeutics Market High Potential Countries, Segments and Strategies

    35.1 Liver Diseases Therapeutics Market In 2029 - Countries Offering Most New Opportunities

    35.2 Liver Diseases Therapeutics Market In 2029 - Segments Offering Most New Opportunities

    35.3 Liver Diseases Therapeutics Market In 2029 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Liver Diseases Therapeutics Market, Sub-Segmentation Of Hepatitis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Liver Diseases Therapeutics Market, Sub-Segmentation Of Non-Alcoholic Fatty Liver Disease (NAFLD), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Liver Diseases Therapeutics Market, Sub-Segmentation Of Alcohol-Induced Liver Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Liver Diseases Therapeutics Market, Sub-Segmentation Of Liver Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Liver Diseases Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Liver Diseases Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Astellas Pharma Inc. Financial Performance
  • Table 79: Bristol-Myers Squibb Company Financial Performance
  • Table 80: F. Hoffmann-La Roche AG Financial Performance
  • Table 81: Merck & Co. Inc. Financial Performance
  • Table 82: Novartis AG Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Liver Diseases Therapeutics Market, Sub-Segmentation Of Hepatitis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Liver Diseases Therapeutics Market, Sub-Segmentation Of Non-Alcoholic Fatty Liver Disease (NAFLD), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Liver Diseases Therapeutics Market, Sub-Segmentation Of Alcohol-Induced Liver Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Liver Diseases Therapeutics Market, Sub-Segmentation Of Liver Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Liver Diseases Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Liver Diseases Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Astellas Pharma Inc. Financial Performance
  • Figure 79: Bristol-Myers Squibb Company Financial Performance
  • Figure 80: F. Hoffmann-La Roche AG Financial Performance
  • Figure 81: Merck & Co. Inc. Financial Performance
  • Figure 82: Novartis AG Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the liver diseases therapeutics market?

Liver disease therapeutics refers to the treatment of numerous types of liver illnesses, diseases brought on by viruses, including hepatitis A, B, and C. Liver disease therapeutics are essential for enhancing the quality of life for those impacted by liver conditions and alleviating the overall strain of liver disease on healthcare systems. For further insights on the liver diseases therapeutics market, request a sample here

How will the liver diseases therapeutics market drivers and restraints affect the liver diseases therapeutics market dynamics? What forces will shape the liver diseases therapeutics industry going forward?

The liver diseases therapeutics market major growth driver - Liver disease therapeutics refers to the treatment of numerous types of liver illnesses, diseases brought on by viruses, including hepatitis A, B, and C. Liver disease therapeutics are essential for enhancing the quality of life for those impacted by liver conditions and alleviating the overall strain of liver disease on healthcare systems.. For further insights on the liver diseases therapeutics market, request a sample here

What is the forecast market size or the forecast market value of the liver diseases therapeutics market?

The liver diseases therapeutics market size has grown strongly in recent years. It will grow from $14.16 billion in 2024 to $15.23 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to high prevalence of liver diseases, alcohol consumption patterns, advancements in diagnostics, obesity and metabolic syndrome, awareness and screening programs, government initiatives for hepatitis control. The liver diseases therapeutics market size is expected to see strong growth in the next few years. It will grow to $20.78 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to precision medicine approaches, innovations in RNA therapeutics, focus on fibrosis treatments, patient advocacy and support groups, development of vaccines for hepatitis, regulatory support for orphan drugs. Major trends in the forecast period include advancements in treatment for hepatitis c, emergence of novel therapies for liver fibrosis, exploration of immunotherapies, telemedicine and remote monitoring, focus on nutritional interventions. For further insights on the liver diseases therapeutics market, request a sample here

How is the liver diseases therapeutics market segmented?

The liver diseases therapeutics market is segmented
1) By Disease Type: Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-Induced, Liver Cancer
2) By Treatment: Antiviral, Vaccines, Chemotherapy, Immunosuppressive Agents, Corticosteroids
3) By End User: Hospitals, Ambulatory Surgery Centers, Other End Users Subsegments:
1) By Hepatitis: Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D
2) By Non-Alcoholic Fatty Liver Disease (NAFLD): Non-Alcoholic Steatohepatitis (NASH), Simple Fatty Liver
3) By Alcohol-Induced Liver Disease: Alcoholic Hepatitis, Alcoholic Cirrhosis
4) By Liver Cancer: Hepatocellular Carcinoma (HCC), CholangiocarcinomaFor further insights on the liver diseases therapeutics market,
request a sample here

Which region has the largest share of the liver diseases therapeutics market? What are the other regions covered in the report?

North America was the largest region in the liver diseases therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the liver diseases therapeutics market, request a sample here.

Who are the major players in the liver diseases therapeutics market?

Major companies operating in the liver disease therapeutics market are focusing on innovative technologies, such as artificial intelligence, to help clinicians identify patients with liver fibrosis early in their disease progression. Artificial intelligence in liver disease therapeutics refers to the application of advanced computational algorithms and machine learning techniques to analyze medical data, aiding in early detection, diagnosis, and personalized treatment strategies for liver diseases. For instance, in February 2023, Predictive Health Intelligence, a UK-based healthcare information management company, launched the hepatoSIGHT. hepatoSIGHT, an innovative AI-powered tool that can predict liver fibrosis in patients with chronic liver disease. It is a case-finding and cohort mapping tool designed to identify patients at risk of chronic liver disease (CLD). It is a secure, intuitive, and easy-to-use system that can review millions of lines of data within seconds to identify patients who meet specified criteria. Moreover, it has features such as comprehensive data analysis, machine learning algorithms, real-time risk stratification, and an easy-to-use interface. For further insights on the liver diseases therapeutics market, request a sample here.

What are the key trends in the liver diseases therapeutics market?

Major trend in the liver diseases therapeutics market - Strategic Partnerships Transforming The Landscape Of Liver Disease Therapeutics. For further insights on the liver diseases therapeutics market, request a sample here.

What are the major opportunities in the liver diseases therapeutics market? What are the strategies for the liver diseases therapeutics market?

For detailed insights on the major opportunities and strategies in the liver diseases therapeutics market, request a sample here.

How does the liver diseases therapeutics market relate to the overall economy and other similar markets?

For detailed insights on liver diseases therapeutics market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the liver diseases therapeutics industry?

For detailed insights on the mergers and acquisitions in the liver diseases therapeutics industry, request a sample here.

What are the key dynamics influencing the liver diseases therapeutics market growth? SWOT analysis of the liver diseases therapeutics market.

For detailed insights on the key dynamics influencing the liver diseases therapeutics market growth and SWOT analysis of the liver diseases therapeutics industry, request a sample here.